Program
cytisine
Also written as “Cytisinicline”, “Cytisine” and “cytisinicline”.
Its studies are mostly in Smoking Cessation · Vaping · Renal Insufficiency, led by Achieve Life Sciences.
Furthest: phase 3, since Sep 25, 202013 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Achieve Life Sciences | 131 open or running | phase 3since Sep 25, 2020 | Aug 25, 2017 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 25, 2017First study: phase 1 study in Smoking CessationFirst studyNCT03268343 · 24 enrolled · United Kingdom
- Sep 28, 2017Phase 2 study in Smoking CessationNCT03303911 · 26 enrolled · United Kingdom
- Apr 17, 2018Phase 1 study in Smoking CessationNCT03509948 · 13 enrolled · United Kingdom
- Oct 15, 2018Phase 2 study in Smoking CessationNCT03709823 · 254 enrolled · United States
- Feb 19, 2019Phase 1 study in Smoking CessationNCT03848208 · 74 enrolled · Portugal
- Sep 25, 2020Phase 3 study in Smoking CessationNCT04576949 · 810 enrolled · United States
- Jan 12, 2022Phase 3 study in Smoking CessationNCT05206370 · 792 enrolled · United States
- Jun 20, 2022Phase 2 study in VapingNCT05431387 · 160 enrolled · United States
- Sep 30, 2022Phase 1 study in Smoking CessationNCT05566288 · 27 enrolled · Portugal
- Oct 18, 2022Phase 1 study in Renal InsufficiencyNCT05631938 · 44 enrolled · Portugal, Spain
- Aug 1, 2023Phase 1 study in Smoking CessationNCT05981768 · 30 enrolled · Portugal
- May 24, 2024Phase 3 study in Smoking CessationNCT06435221 · 479 enrolled · United States
- Jan 20, 2026Phase 3 study in Vaping CessationNCT07392125 · 800 planned
Ahead
- Nov 15, 2026Primary completion: phase 3 study in Vaping CessationNCT07392125
TargetBeta
“Neuronal acetylcholine receptor; alpha4/beta2 partial agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Vareniclinerule | Pfizer | phase 4 | 45 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07392125Vaping Cessation | 3 | Not yet recruiting | Nov 15, 2026 | 800 |
| NCT06435221Smoking Cessation · United States | 3 | Completed | Sep 29, 2025 | 479 |
| NCT05981768Smoking Cessation · Portugal | 1 | Completed | Sep 21, 2023 | 30 |
| NCT05631938Renal Insufficiency · Portugal, Spain | 1 | Completed | Sep 4, 2023 | 44 |
| NCT05566288Smoking Cessation · Portugal | 1 | Completed | Dec 23, 2022 | 27 |
| NCT05431387Vaping · United States | 2 | Completed | Feb 28, 2023 | 160 |
| NCT05206370Smoking Cessation · United States | 3 | Completed | Mar 21, 2023 | 792 |
| NCT04576949Smoking Cessation · United States | 3 | Completed | Dec 23, 2021 | 810 |
| NCT03848208Smoking Cessation · Portugal | 1 | Completed | Sep 12, 2019 | 74 |
| NCT03709823Smoking Cessation · United States | 2 | Completed | Apr 23, 2019 | 254 |
| NCT03509948Smoking Cessation · United Kingdom | 1 | Completed | Jun 10, 2018 | 13 |
| NCT03303911Smoking Cessation · United Kingdom | 2 | Terminated | Oct 5, 2018 | 26 |
| NCT03268343Smoking Cessation · United Kingdom | 1 | Completed | Aug 26, 2017 | 24 |
How it is read
Names in the registry
- “Cytisinicline”, 6 entries
- “Cytisine”, 3 entries
- “cytisinicline”, 2 entries
- “cytisine”, 2 entries
Conditions, from the studies’ own filings
- Smoking Cessation, 10 studies
- Vaping, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.